Replication-deficient modified vaccinia ankara (mva) expressing marburg virus glycoprotein (gp) and matrix protein (vp40)

A method of preventing an infection by a Marburg virus in a human subject at risk of exposure thereto, said method comprising administering to the human subject in need thereof a pharmaceutical composition in a prophylactically effective amount, wherein the pharmaceutical composition comprises:

• a) at least one recombinant modified vaccinia ankara (MVA) vector comprising:
• i) a first nucleic acid sequence encoding a Marburg virus glycoprotein comprising nucleic acids 1631-3676 of SEQ ID NO:
• 15, or a nucleic acid sequence at least 95% identical thereto, and
• ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein comprising nucleic acids 1581-2492 of SEQ ID NO:
• 14, or a nucleic acid sequence at least 95% identical thereto;
• wherein both the first nucleic acid sequence and the second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems;
• wherein the first nucleic acid is located between MVA genes I8R and G1L;
• wherein the second nucleic acid sequence is located between MVA genes A50R and B1R in a restructured and modified deletion site III;
• and
• wherein the Marburg virus glycoprotein and the Marburg virus VP40 matrix protein are capable of assembling into virus-like particles (VLPs) when expressed in a host cell;
• and
• b) a pharmaceutically acceptable carrier.